At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,360 enrolled
Drug / intervention
MaxSpiolto® Respimat® 160 Characters...drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto® Respimat® [ELLACTO]
In Brief
An observational study evaluating MaxSpiolto® Respimat® 160 Characters... for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 1,360 participants across 15 sites.
Detailed Summary
Open-label observational study: including COPD patients receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesGreece
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMar 2018
Primary CompletionNov 2018
Study CompletionApr 2019
TodayJul 2026
First PostedFeb 5, 2018
Enrollment StartMar 19, 2018
Primary CompletionNov 9, 2018
Study CompletionApr 3, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.4 years ago
Interventions
MaxSpiolto® Respimat® 160 Characters...drug
as per the approved SmPC